{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:35:09Z","timestamp":1787502909469,"version":"build-2736575974"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biochemical recurrence after radiotherapy is common and clinically challenging in prostate cancer (PCa), as accurate restaging is required to identify patients eligible for local salvage therapy and distinguish them from those requiring systemic or metastasis-directed treatment. This review evaluates the diagnostic value of multiparametric MRI (mpMRI) and prostate-specific membrane antigen\u2013targeted PET\/CT (PSMA-targeted PET\/CT) for restaging radiorecurrent prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A narrative review was conducted using PubMed and Scopus. Original English-language studies published within the last 10 years were included if they reported the diagnostic performance of mpMRI, PSMA-targeted PET\/CT, or combined imaging in patients with suspected radiorecurrent prostate cancer, using histopathology as the reference standard. Evidence was synthesized with particular attention to intraprostatic recurrence, extraprostatic disease, and imaging performance after brachytherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten studies (4 prospective and 6 retrospective) met the inclusion criteria. mpMRI demonstrated heterogeneous sensitivity for intraprostatic recurrence with moderate-to-high specificity (64\u201387%), and frequently underestimated multifocal disease, particularly in the post-brachytherapy setting. PSMA-targeted PET\/CT showed high sensitivity for intraprostatic recurrence (up to ~89%) and superior detection of nodal and distant metastases, although very small or low\u2013PSMA-expressing intraprostatic lesions may remain undetected. The combination of mpMRI and PSMA-targeted PET\/CT provided the highest diagnostic confidence: concordant findings achieved a positive predictive value of 97.6%, supporting improved patient selection for salvage treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>mpMRI and PSMA-targeted PET\/CT provide complementary diagnostic information rather than being interchangeable modalities. A multimodal imaging approach improves restaging accuracy in radiorecurrent prostate cancer and may better guide biopsy targeting and selection of candidates for salvage therapy. Nevertheless, histological confirmation remains mandatory before local salvage treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1782344","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:22:41Z","timestamp":1776745361000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The diagnostic value of mpMRI and PSMA-targeted PET\/CT in radiorecurrent prostate cancer: a narrative review"],"prefix":"10.3389","volume":"16","author":[{"given":"Umberto","family":"Merani","sequence":"first","affiliation":[{"name":"Department of Surgical Sciences, Division of Urology, Molinette Hospital, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Venturi","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Division of Urology, Molinette Hospital, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Calleris","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Division of Urology, Molinette Hospital, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Dematteis","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Division of Urology, Molinette Hospital, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Carlo","family":"Iorio","sequence":"additional","affiliation":[{"name":"Department of Oncology, Radiation Oncology Unit, Molinette Hospital, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Marquis","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Division of Urology, Molinette Hospital, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Sasia","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Division of Urology, Molinette Hospital, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Marra","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Division of Urology, Molinette Hospital, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Division of Urology, Molinette Hospital, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Oderda","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences, Division of Urology, Molinette Hospital, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv222","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Parker","year":"2015","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer","volume":"24","author":"Valle","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2020.1822742","article-title":"Prostate re-irradiation: Current concerns and future perspectives","volume":"20","author":"Cuccia","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1636563","article-title":"International consensus radiochemistry nomenclature guidelines","volume":"57","author":"Coenen","year":"2018","journal-title":"Nuklearmedizin"},{"key":"B6","doi-asserted-by":"publisher","first-page":"128\u201336","DOI":"10.1038\/pcan.2014.55","article-title":"Multiparametric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic contrast-enhanced images","volume":"18","author":"Abd-Alazeez","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2016.06.003","article-title":"Detection of recurrent prostate cancer after primary radiation therapy: An evaluation of the role of multiparametric 3T magnetic resonance imaging with endorectal coil","volume":"7","author":"Zattoni","year":"2017","journal-title":"Am Soc For Radiat Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.12.025","article-title":"18F-choline positron emission tomography\/ computed tomography and multiparametric magnetic resonance imaging for the detection of early local recurrence of prostate cancer initially treated by radiation therapy: Comparison with systematic 3-dimensional transperineal mapping biopsy","volume":"97","author":"Kanoun","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-018-5819-y","article-title":"Quantitative 3-T multi-parametric MRI and step-section pathology of recurrent prostate cancer patients after radiation therapy","volume":"29","author":"Fernandes","year":"2019","journal-title":"Eur Radio"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20201423","article-title":"Detection and staging of radio-recurrent prostate cancer using multiparametric MRI","volume":"94","author":"Kowa","year":"2021","journal-title":"Br J Radiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.eururo.2022.02.022","article-title":"Magnetic resonance imaging and targeted biopsies compared to transperineal mapping biopsies before focal ablation in localised and metastatic recurrent prostate cancer after radiotherapy","volume":"81","author":"Shaha","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030781","article-title":"Value of targeted biopsies and combined PSMA PET\/CT and mp-MRIimaging in locally recurrent prostate cancer after primary radiotherapy","volume":"14","author":"Rasing","year":"2022","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.eururo.2023.09.001","article-title":"The role of multiparametric MRI and MRI\u2013targeted biopsy in the diagnosis of radiorecurrent prostate cancer: An analysis from the FORECAST trial","volume":"85","author":"Light","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266527","article-title":"Diagnostic performance of 68Ga-PSMA-11 PET\/CT versus multiparametric MRI for detection of intraprostatic radiorecurrent prostate cancer","volume":"65","author":"Light","year":"2024","journal-title":"J Nucl Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijrobp.2025.02.042","article-title":"The importance of multiparametric magnetic resonance imaging, positron emission tomography\/computed tomography, and biopsy for identifying and delineating the extent of intraprostatic radiorecurrent prostate cancer: A secondary analysis of the F-SHARP clinical trial","author":"Venkatesulu","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: A systematic review and meta-analysis","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-023-04383-2","article-title":"Magnetic resonance imaging (MRI) for local staging before salvage radical prostatectomy: A meta-analysis","volume":"41","author":"Zapa\u0142a","year":"2023","journal-title":"World J Urol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.11.001","article-title":"A prospective study of 18F-DCFPyL PSMA PET\/CT restaging in recurrent prostate cancer following primary external beam radiotherapy or brachytherapy","volume":"106","author":"Liu","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12880-019-0380-y","article-title":"Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): A prospective cohort, observational diagnostic accuracy trial investigating whole-body magnetic resonance imaging in radio-recurrent prostate cancer","volume":"19","author":"Adeleke","year":"2019","journal-title":"BMC Med Imaging"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3056\u201363","DOI":"10.1007\/s00259-025-07699-w","article-title":"PSMA PET\/CT for the detection of prostate cancer biochemical recurrence after primary radiation therapy: Is it time to review the Phoenix criteria","volume":"53","author":"Evangelista","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.01.003","article-title":"Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): International consensus -based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy","volume":"4","author":"Panebianco","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/RLU.0000000000006168","article-title":"Validation of the PSMA PRIMARY scoring system and comparison to an E-PSMA Likert system for [68Ga]Ga-PSMA-11 PET\/CT interpretation in men with suspected radiorecurrent prostate cancer","volume":"51","author":"Light","year":"2026","journal-title":"Clin Nucl Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10851-0","article-title":"ROADSTER: A phase II trial of 177Lu-PSMA radioligand therapy in prostate cancer","volume":"23","author":"Mendez","year":"2023","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1782344\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:22:42Z","timestamp":1776745362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1782344\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":24,"alternative-id":["10.3389\/fonc.2026.1782344"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1782344","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"article-number":"1782344"}}